{"id":37727,"date":"2017-01-18T09:37:16","date_gmt":"2017-01-18T14:37:16","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37727"},"modified":"2017-01-18T09:37:16","modified_gmt":"2017-01-18T14:37:16","slug":"gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727","title":{"rendered":"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>GW Pharmaceuticals (NASDAQ:GWPH)<\/strong> did not have a rosy walk for 2016 with revenue dropping 62% on a year-over-year basis. The company also reported a $21.8 million loss for the last quarter. With a record like this, the investors would have dreamt of red marks in the first week of 2017 itself. But, a surprise of all surprises is the company called GW Pharmaceuticals, whose stock woke up to a healthy start of the New Year.<\/p>\n<h2 style=\"text-align: justify;\"><strong>The healthy start to New Year<\/strong><\/h2>\n<p style=\"text-align: justify;\">We are almost half way through the first month of this year, and it is an ideal time to analyze what the shares were in 2016 and how they are responding this year. Albeit not expected, but the company\u2019s shares showed a positive sign with an upward trend of 5.5% in the new trading week of this year. This can be attributed to GW Pharmaceuticals\u2019 flagship therapies, through which, the company aims to treat rare forms of epilepsy. The results of efficacy in finishing stages of trials show positive sign.<\/p>\n<h2 style=\"text-align: justify;\"><strong>The flagship therapies may push up company\u2019s fortune for 2017<\/strong><\/h2>\n<p style=\"text-align: justify;\">GW Pharmaceuticals is now waiting for its drug\u2019s approval from the authorities, after which, the flagship therapies for epilepsy will join company\u2019s other commercial drugs.<\/p>\n<h2 style=\"text-align: justify;\"><strong>Anything special about this? <\/strong><\/h2>\n<p style=\"text-align: justify;\">Well, yes! The impressive part is that both the drugs of this company are based on medical cannabis and medical marijuana, thereby bolstering the plant\u2019s legitimacy. So, while there are a range of marijuana stocks in the market, this one is something that is for the serious investors. When it comes to the marijuana market, this company plays it right.<\/p>\n<p style=\"text-align: justify;\">Remember the fact that GW Pharmaceuticals is among those drug called Sativex was the first one to seek approval as the prescription-based cannabis drug. UK was the first one to give it a nod in 2010 and after that, this drug has been approved in other 29 countries as well.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GW Pharmaceuticals (NASDAQ:GWPH) did not have a rosy walk for 2016 with revenue dropping 62% on a year-over-year basis. The company also reported a $21.8 [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":16662,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12212,12211,4909],"stock_ticker":[],"class_list":["post-37727","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-gw-pharmaceuticals","tag-gw-pharmaceuticals-nasdaqgwph","tag-nasdaqgwph","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"GW Pharmaceuticals (NASDAQ:GWPH) did not have a rosy walk for 2016 with revenue dropping 62% on a year-over-year basis. The company also reported a $21.8 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-18T14:37:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"110\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune\",\"datePublished\":\"2017-01-18T14:37:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727\"},\"wordCount\":329,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png\",\"keywords\":[\"GW Pharmaceuticals\",\"GW Pharmaceuticals (NASDAQ:GWPH)\",\"NASDAQ:GWPH\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727\",\"name\":\"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png\",\"datePublished\":\"2017-01-18T14:37:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png\",\"width\":200,\"height\":110},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727","og_locale":"en_US","og_type":"article","og_title":"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune - Wall Street PR","og_description":"GW Pharmaceuticals (NASDAQ:GWPH) did not have a rosy walk for 2016 with revenue dropping 62% on a year-over-year basis. The company also reported a $21.8 [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-01-18T14:37:16+00:00","og_image":[{"width":200,"height":110,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png","type":"image\/png"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune","datePublished":"2017-01-18T14:37:16+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727"},"wordCount":329,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png","keywords":["GW Pharmaceuticals","GW Pharmaceuticals (NASDAQ:GWPH)","NASDAQ:GWPH"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727","url":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727","name":"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png","datePublished":"2017-01-18T14:37:16+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/GW-Pharmaceuticals-PLC.png","width":200,"height":110},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gw-pharmaceuticals-nasdaqgwph-epilepsy-flagship-therapies-may-brighten-companys-fortune-37727#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"GW Pharmaceuticals (NASDAQ:GWPH) Epilepsy Flagship Therapies May Brighten Company\u2019s Fortune"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37727"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37727\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/16662"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37727"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}